ZLDAF (Zelira Therapeutics) Institutional Ownership: 0.03% (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZLDAF Zelira Therapeutics Ltd ZLDAF
9 GF Score
Price $0.30
GF Value $0.06
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Zelira Therapeutics Institutional Ownership?

Zelira Therapeutics ZLDAF 9 Institutional Ownership is 0.03% as of Jul. 17, 2026. GuruFocus rates ZLDAF with a GF Score™ of 9/100 and a GF Value™ of $0.06 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Zelira Therapeutics's institutional ownership is 0.03%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Zelira Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Zelira Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.

Zelira Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Institutional Ownership Chart

Zelira Therapeutics Historical Data

The historical data trend for Zelira Therapeutics can be seen below:

2016-04-30 2016-05-31 2016-06-30 2016-07-31 2016-08-31 2016-09-30 2018-03-31 2018-04-30 2018-05-31 2018-06-30
Institutional Ownership 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.06 0.06 0.03
ZLDAF
9GF Score
Zelira Therapeutics Ltd ZLDAF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zelira Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.03% mean?
Zelira Therapeutics (ZLDAF) has a Institutional Ownership of 0.03% as of Jul. 17, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Institutional Ownership too high?
Zelira Therapeutics' current Institutional Ownership is 0.03%. Overall, Zelira Therapeutics has a GF Score™ of 9/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zelira Therapeutics' Institutional Ownership compare to MTNB and SXTP?
Zelira Therapeutics' Institutional Ownership of 0.03% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Institutional Ownership is 0.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zelira Therapeutics (ZLDAF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.06, compared to a current price of $0.30 — trading 400% above its estimated fair value. The current Institutional Ownership is 0.03%. Zelira Therapeutics' overall GF Score™ is 9/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Zelira Therapeutics (ZLDAF), the current Institutional Ownership is 0.03% as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zelira Therapeutics (ZLDAF) Overvalued in 2026?

Based on GuruFocus' analysis, Zelira Therapeutics stock appears to be overvalued. The current stock price of $0.30 is trading 400% above its estimated GF Value™ of $0.06. GuruFocus considers Zelira Therapeutics to be Significantly Overvalued.

Key valuation signals for ZLDAF:

  • Institutional Ownership: 0.03%
  • GF Value™: $0.06 vs. price of $0.30 (400% above fair value)
  • GF Score™: 9/100 with 7 warning signs

No single metric tells the full story. See the ZLDAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zelira Therapeutics Business Description

Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
9GF Score

Get the complete analysis for ZLDAF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30
Price
$0.06
GF Value